The earnings call reflects a mixed performance for Hikma in the first half of 2025. While there was notable revenue growth and strategic advancements, challenges such as declining core operating profit and increased costs impacted overall performance. However, the company maintains a positive outlook for the second half, supported by strategic investments and robust balance sheet management.

Company Guidance

The guidance provided during the Hikma 2025 half-year results presentation highlighted robust metrics across various segments. The company achieved a 6% revenue growth driven by strong volumes and successful launches, despite a 7% decline in core operating profit to $373 million due to regional and product mix challenges, FX headwinds, and strong previous year comparisons. Core EBITDA and core basic earnings per share both saw a 5% year-on-year decline. The Injectables segment experienced a 12% revenue increase with a 30% core operating margin, albeit lower than the previous year's 36.3%, influenced by product mix and euro appreciation. The Branded business reported a 4% revenue growth and a 3% operating profit increase, maintaining a 30% operating margin, while the Rx division faced an 11% gross profit contraction due to pricing pressures. Operational cash flow decreased to $161 million from $198 million, impacted by tax payment timing. The company reiterated its full-year guidance with a 4% to 6% revenue growth expectation and a core operating profit range of $730 million to $770 million, adjusting segmental margins due to currency and cost pressures. Investments in R&D and manufacturing, alongside strategic partnerships, are set to drive future growth, with a low leverage ratio of 1.7x supporting continued financial stability.

Strong Revenue Growth

Hikma delivered a 6% revenue growth driven by robust volumes across all business segments and regions, with recent launches and the Xellia acquisition contributing to growth.

Injectables Segment Performance

Injectables segment showed consistent strong momentum with a 12% core revenue growth year-on-year, supported by the Xellia acquisition and strong demand in Europe and MENA.

Strategic Partnerships and Pipeline Expansion

Hikma signed new strategic partnerships and enhanced manufacturing capabilities, significantly expanding its pipeline and positioning for future growth.

Strong Performance in Europe and MENA

European revenue grew by 26% and MENA by 16% in the Injectables segment, driven by expanding portfolios and market shortages.

Branded Segment Growth

The Branded segment delivered 4% top-line growth and 3% operating profit growth, maintaining a strong position as the second largest pharmaceutical company in MENA.

Robust Balance Sheet

Hikma maintained a robust balance sheet with a leverage ratio below 2x at 1.7x net debt to core EBITDA, despite higher debt utilization for acquisitions.

Hikma Pharmaceuticals (HKMPY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HKMPY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 19, 2026	2025 (Q4)	- / -	1.194	―	―	―
Aug 07, 2025	2025 (Q2)	- / 2.17	2.038	6.38% (+0.13)	―	―
Feb 26, 2025	2024 (Q4)	- / 1.21	0.536	125.00% (+0.67)	―	―
Aug 08, 2024	2024 (Q2)	- / 2.04	1.186	71.84% (+0.85)	―	―
Feb 22, 2024	2023 (Q4)	- / 0.54	0.136	294.12% (+0.40)	―	―
Aug 03, 2023	2023 (Q2)	- / 1.19	1.524	-22.18% (-0.34)	―	―
Feb 23, 2023	2022 (Q4)	- / 0.14	1.496	-90.91% (-1.36)	―	―
Aug 04, 2022	2022 (Q2)	- / 1.52	2.147	-29.02% (-0.62)	―	―
Feb 24, 2022	2021 (Q4)	- / 1.50	1.926	-22.33% (-0.43)	―	―
Aug 06, 2021	2021 (Q2)	- / 2.15	1.752	22.55% (+0.39)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HKMPY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$49.50	$46.24	-6.59%
Feb 26, 2025	$56.24	$52.94	-5.87%
Aug 08, 2024	$44.79	$48.46	+8.19%
Feb 22, 2024	$47.31	$49.37	+4.35%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Hikma Pharmaceuticals PLC (HKMPY) report earnings?

Hikma Pharmaceuticals PLC (HKMPY) is schdueled to report earning on Feb 19, 2026, TBA (Confirmed).

What is Hikma Pharmaceuticals PLC (HKMPY) earnings time?

Hikma Pharmaceuticals PLC (HKMPY) earnings time is at Feb 19, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is HKMPY EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing